Grab Key Details And Sources Here: Company Website - Company Presentation
-----
As mentioned above, BSGM has several potential breakout catalysts to soak in right now. Here they are:
No. 1 BSGM Potential Catalyst - A 2023 Analyst Provided Target Suggests Upwards Of 300% Potential Upside
In February of 2023, Ascendiant Capital Markets' analyst, Edward Woo, tagged BSGM with a $5.00 target.
From its closing valuation on Tuesday, that provides BSGM with an upside potential over 300%.
Here's some key highlights from the report:
Focused on PURE EP: The company has developed the PURE EP system whose enhanced signal acquisition, digital signal processing, and analysis provides key data used during ablation of cardiac arrhythmias. The PURE EP System is a FDA 510(k) cleared (in August 2018) non-invasive class II device.
Targeting heart disease: In the U.S., heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups, contributing to about 20 - 25% of deaths in the U.S. every year. Every 40 seconds, someone in the U.S. has a heart attack. Arrhythmia is a leading condition and contributing cause for heart disease.
PURE EP system: The PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP (Electrophysiology) System is designed to provide essential diagnostic signals during all types of cardiac catheter ablations (a procedure that involves delivery of energy through the tip of a catheter to correct heart rhythm arrhythmias). PURE EP is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials.
PURE EP benefits: PURE EP’s features may allow physicians to better determine precise ablation targets, strategy, and end point of procedures with the objective of reducing the need for patients to undergo multiple procedures, and to allow for less experienced EP physicians to perform more complex procedures. It is estimated that over half of cardiac ablation procedures are not successful (requires additional ablation procedures).
3,000 procedures and growing: To date, more than 3,000 patient procedures have been conducted with the PURE EP System by more than 80 electrophysiologists across 21 different clinical sites in the U.S. The PURE EP System is currently in national commercial launch in the U.S. at healthcare systems such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.
Market opp's: According to Health Research International, it is estimated that there are 8,163 global EP lab rooms (with an estimated 3,500 in the U.S.) performing catheter ablations. The rapidly growing EP market is projected to reach $16Bn by 2028 (+11.2% annual growth rate).
However, challenges exist: BioSig operates in a highly competitive environment and competes against a wide range of other technologies. There is the chance that competing technologies may challenge BioSig technologies or that existing standard of care methods remains the industry standard.
...
Current valuation attractive: We calculate a 12-month price target for shares of BioSig to be $5.00 based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company’s high risks with its high growth prospects and large upside opp's.
-----
No. 2 BSGM Potential Catalyst - Company Inks New Collaboration Deal To Advance AI In Electrophysiology
BioSig Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare
Westport, CT, June 27, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is advancing the research and development of an artificial intelligence (AI) medical device platform in collaboration with technical advisory partner Reified Labs.
The platform’s foundational machine learning model is anticipated to be based on integrated healthcare datasets, beginning with ECG and IECG data acquired by BioSig’s first product, the PURE EP™ Platform. Electrophysiology-focused technological solutions developed under the terms of the collaboration may be integrated into PURE EP™ technology for potential commercial application.
Cambridge, Massachusetts-based Reified Labs, a provider of advanced artificial intelligence-focused technical advisory services to the life sciences industry, is led by Harvard- and MIT-trained Dr. Alexander D. Wissner-Gross, an award-wi-nning computer scientist, physicist, entrepreneur, and author. BioSig's prior collaboration with Reified, established in 2019, has yielded multiple patent applications1 and a research publication2 on initial discoveries in AI-enhanced electrocardiogram lead placement mapping.
On June 20, 2023, Dr. Wissner-Gross delivered a keynote address at a prominent gathering of clinical leaders in Rochester, Minnesota, exploring the exciting possibilities that artificial intelligence brings to healthcare. In his speech, entitled “Unsupervised Medicine: The Next Wave of AI in Healthcare,” Dr. Wissner-Gross reviewed recent research advances in unsupervised (or self-supervised) machine learning models. Such models appear to have dramatically accelerated overall progress toward artificial general intelligence (AGI), with one community forecast of the expected arrival date of AGI collapsing from 2043 to 2026 in the past two years alone. In describing AGI and how its applications can be accelerated in healthcare, Dr. Wissner-Gross used Reified’s prior collaboration with BioSig as a case study.
“The cutting-edge work this collaboration started in early 2019 to lay a foundation in AI was ahead of the curve, and our initial findings may have several potentially valuable clinical applications worthy of further exploration,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
“The application of AGI and digital signal processing to analyzing signals from the so-called human ‘electrome’ – the set of all electrical and ionic currents in the human body – continues to present a promising opp. for realizing key medical advances relating to disorders of the peripheral nervous system,” said Dr. Wissner-Gross. “We look forward to our forthcoming collaboration with BioSig.”
Read the full article here.
-----
No. 3 BSGM Potential Catalyst - New Data Puts Company On Track For A Successful Commercial Launch
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6Bn Annual Atrial Fibrillation Market
WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week. The platform's precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation. All three studies showed significant improvements over the conventional methods used for the procedure, putting BioSig on track for a successful commercial launch of the platform in a global cardiac ablation market projected to exceed $14Bn by 2032.
...
PURE EP Platform Captures Real-Time Feedback Other Tech Misses
While the Ablation Index uses surrogate measures, including contract force, power and time, PURE EP uses raw unipolar signals to generate real-time feedback. In the past, studies have suggested that using these unipolar signals could improve the accuracy of ablations, but actually capturing those signals proved impractical as there was too much noise interference from the operating room as well as the radio frequency equipment used in the procedure.
The PURE EP platform's proprietary hardware and software can dampen noise interference and pick up the unipolar signal clearly and in real-time with a level of precision that other platforms reportedly can't achieve.
To understand how much of a difference this improved signal-capturing tech made in the operating room, the three studies presented at Heart Rhythm 2023 each compared a new cardiac ablation procedure using BioSig's PURE EP Platform to the current best-in-class Ablation Index-guided procedure.
In the first study, the new procedure was able to achieve identical results in both swine and human models in a fraction of the time. Where the standard ablation index-guided procedure had an ablation time of 24 seconds, the PURE EP-guided procedure's ablation time was just eight seconds.
In the second study, doctors performed the surgery without the 3D mapping system traditionally used. Instead, they were able to accurately place and space lesions in swine models guided only by the PURE EP Platform's unipolar morphology.
In the third study, researchers found that the platform could successfully differentiate between healthy tissue and scar tissue, allowing doctors to better measure lesions for more precise lesion placement.
Already used in several hospitals across the country, BioSig is optimistic that the non-invasive platform could see even wider spread adoption of the technology following the release of these three studies demonstrating the improved speed, accuracy and precision of cardiac ablations done with the PURE EP Platform.
Read the full article here.
-----
No. 4 BSGM Potential Catalyst - An Explosive Chart History Oozing With Major Breakout Splashes
Take a quick look at BSGM's 1-year chart below:
